According to the latest report by IMARC Group “Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global hemophilia market size reached US$ 11.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028.
Hemophilia is a genetic medical condition that impacts the blood clotting mechanism of the body. It causes abnormal blood clots, leading to excessive bleeding, easy bruising, and oozing after an injury, surgery, or dental procedure. It occurs due to a hereditary deficiency in coagulation factor that inhibits blood clotting by limiting the availability of necessary blood-clotting proteins. Its treatment primarily focuses on replacing the missing proteins and preventing potential complications. At present, hemophilia can be treated through medications, replacement therapy, and injections of a clotting factor or plasma across the globe.
Request for a free sample copy of this report: https://www.imarcgroup.com/hemophilia-market/requestsample
Market Trends:
The global hemophilia market is primarily driven by the increasing number of patients with hemophilia and a rise in genetic abnormalities across the globe. Additionally, the surging popularity of prophylactic treatment and the rising diagnosis rate of illness is positively influencing the market growth. Moreover, several favorable initiatives by governments of numerous countries to spread awareness about the benefits of early diagnosis and proper procedures for early screening of neonates have catalyzed market growth. Furthermore, several key players are focusing on introducing technologically advanced diagnostic tools and therapies to improve the effectiveness and precision of hemophilia treatment, thereby contributing to market growth. Other factors, including increasing funding for research and development (R&D) activities, the rapid expansion of specialized hemophilia treatment centers (HTCs), and rising demand for early diagnosis of hemophilia, are also anticipated to drive the market further.
Breakup by Type:
- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Breakup by Treatment:
- On-Demand
- Prophylaxis
Breakup by Therapy:
- Replacement Therapy
- ITI Therapy
- Gene Therapy
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Competitive Landscape with Key Player:
- Baxter International Inc.
- Bayer AG
- BioMarin Pharmaceutical Inc.
- CSL Behring (CSL Limited)
- F. Hoffmann-La Roche AG
- Grifols S.A.
- Kedrion S.p.A.
- Novo Nordisk A/S
- Octapharma AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited.
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/hemophilia-market
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal
